GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kura Oncology Inc (NAS:KURA) » Definitions » Earnings Yield (Joel Greenblatt) %

Kura Oncology (Kura Oncology) Earnings Yield (Joel Greenblatt) % : -14.93% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Kura Oncology Earnings Yield (Joel Greenblatt) %?

Kura Oncology's Enterprise Value for the quarter that ended in Mar. 2024 was $1,114.78 Mil. Kura Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-166.50 Mil. Kura Oncology's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2024 was -14.93%.

The historical rank and industry rank for Kura Oncology's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

KURA' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -147.06   Med: 0   Max: 0
Current: -15.6

KURA's Earnings Yield (Joel Greenblatt) % is ranked worse than
51.21% of 1408 companies
in the Biotechnology industry
Industry Median: -14.54 vs KURA: -15.60

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Kura Oncology's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Kura Oncology Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Kura Oncology's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kura Oncology Earnings Yield (Joel Greenblatt) % Chart

Kura Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.85 -5.77 -30.86 -31.95 -22.83

Kura Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.77 -43.29 -58.48 -22.83 -14.93

Competitive Comparison of Kura Oncology's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Kura Oncology's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kura Oncology's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kura Oncology's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Kura Oncology's Earnings Yield (Joel Greenblatt) % falls into.



Kura Oncology Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Kura Oncologys Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-151.082/662.396
=-22.81 %

Kura Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-166.50 Mil.



Kura Oncology  (NAS:KURA) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Kura Oncology Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Kura Oncology's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kura Oncology (Kura Oncology) Business Description

Industry
Traded in Other Exchanges
Address
12730 High Bluff Drive, Suite 400, San Diego, CA, USA, 92130
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.
Executives
Brian T. Powl officer: Chief Commercial Officer C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131
Thomas Malley director C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas James Doyle officer: SVP, Finance & Accounting C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Kirsten Flowers officer: Chief Commercial Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Kathleen Ford officer: Chief Operating Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Stephen Dale officer: Chief Medical Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Teresa Brophy Bair officer: Chief Legal Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Helen Louise Collins director TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Carol Schafer director 42 WHITE STREET, FOURTH FLOOR, NEW YORK NY 10013
Troy Edward Wilson director, officer: President and CEO C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Marc Grasso officer: CFO, CBO C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Bridget A Martell officer: Acting Chief Medical Officer C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
James Basta officer: Chief Legal Officer C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Antonio Gualberto officer: Chief Medical Officer 245 FIRST STREET, SUITE 1820, CAMBRIDGE MA 02142